Barrington analyst Michael Petusky lowered the firm’s price target on Merit Medical (MMSI) to $107 from $109 and keeps an Outperform rating on the shares, citing the short-term dilutive impact of the View Point transaction as the primary reason for the firm’s lowered target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target lowered to $96 from $106 at Piper Sandler
- Merit Medical Recasts Revenue to Highlight Growing Therapies
- Merit Medical price target lowered to $100 from $107 at BTIG
- Merit Medical management to meet with Barrington
- Merit Medical price target lowered to $90 from $99 at Canaccord